Solna, Sweden, June 13, 2022 – Vivesto AB (“Vivesto” or the “Company”), an oncology-focused specialty pharmaceutical company, hereby announces that the Board of Directors of the Company has today agreed with the Company’s CEO, Francois Martelet, to mutually terminate his employment. Pursuant to the agreement, Francois’ employment will end on 21 July 2022.
Vivesto has commenced the search for a new CEO.
Francois Martelet has been CEO since 15 March 2020.
Peter Zonabend, Chairman of the Board of Vivesto, said: “On behalf of the Board, I would like to express my gratitude to Francois for his service and determination during his tenure at Vivesto. We wish him the best for his next endeavours.”
Francois Martelet said: “It has been an incredible honour to lead Vivesto during this period of transformation and I am pleased about what we have achieved together. My team and I are proud to have strengthened Vivesto’s finances in a challenging market environment and to have started the ‘string of pearls’ strategy to build Vivesto’s pipeline through in-licensing and M&A. I want to offer my thanks to the Board, and I wish Vivesto every success for the future.”
For More Information:
Vivesto AB
Peter Zonabend, Chairman of the Board of Vivesto
Phone: +46 18-50 54 40
E-mail: IR@vivesto.com
Consilium Strategic Communications (For Vivesto)
Jonathan Birt, Ashley Tapp
Phone: +44 (0) 20 3709 5700
E-mail: vivesto@consilium-comms.com